News
-
-
PRESS RELEASE
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
Tharimmune, Inc. announces Phase 2 study for TH104 to treat pruritus in primary biliary cholangitis patients. Company achieved key milestones in 2024 -
-
-
-
PRESS RELEASE
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Tharimmune, Inc. presents promising Phase 1 TH104 clinical data at The Liver Meeting® 2024, demonstrating significant correlation between blood levels and symptom relief in chronic liver disease patients -
-
PRESS RELEASE
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Tharimmune, Inc. announces the European Patent Office intends to grant a patent for biodegradable polymeric nanoparticles designed to enhance therapeutic delivery in cancer therapies. The innovative platform aims to reduce side effects and improve therapy effectiveness -
-
